Abstract
INTRODUCTION
Colorectal cancer (CRC) is the third most common cancer and ranks fourth as a cause of death world wide [1] . Endoscopic polypectomy is a safe and useful procedure to prevent CRC, reducing the CRC morbidity by 70%80% [2, 3] . Postpolypectomy bleeding (PPB) is the most common complication of endoscopic polypectomy with reported incidences ranging from 0.65% to 8.6% [46] . Risk factors for PPB include larger polyp size, right colon, pedunculated type and anticoagulants [69] , although these are still controversial. Major guidelines recommend cessation of anticoagulants before polypectomy and heparin bridge therapy for high thrombotic risk cases [1012] . Nevertheless, a study demonstrated that the incidence of PPB was higher in patients taking anticoagulants, even if they were interrupted [13] . Recently, another study suggested that heparin bridge therapy might be associated with a higher PPB rate in patients taking anticoagulants [14] . Studies, including a metaanalysis, suggest that bridging therapy might be associated with high bleeding risk after invasive procedures including polypectomy in patients taking anticoagulants [15, 16] .
A randomized doubleblind placebocontrolled trial demonstrated that bleeding risk was higher in patients taking bridging therapy than in those without bridging and that thromboembolic risk was similar in both groups [17] . The aim of this study was to elucidate the risk factors for PPB including antithrombotic agents and heparin bridge therapy.
MATERIALS AND METHODS
This is a casecontrol study based on medical records at Sapporo Medical University Hospital. All colonos copic polypectomies, endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) performed between January 2011 and December 2014 were included. Patient, polyp and procedure related factors were obtained from the database. The patient related factors included age, gender, comorbidity, antithrombotic agents (antiplatelet and anticoagulant). The polyprelated factors included location (right colon: cecum, ascending colon, and transverse colon; left colon: descending colon, sigmoid colon, and rectum), size, shape and number of resected polyp. The procedurerelated factors were prophylactic clipping and resection method (polypectomy, EMR or ESD). PPB was defined as bleeding that occurred 6 h to 10 d after colonoscopic polypectomy and required endoscopic hemostasis. For such cases, a secondlook colonoscopy was performed to identify the origin of the bleeding and endoscopic hemostasis was performed immediately.
The management of antithrombotic agents was based on the Japanese Gastroenterological Endo scopy Society guidelines published in 2005 [18] . The instrument used for polypectomy and EMR was a SnareMaster (Olympus medical, Tokyo, Japan) and normal saline was injected for EMR. The instruments used for ESD were a Hook knife (Olympus medical, Tokyo, Japan) or Flush Knife BT (Fujifilm, Tokyo, Japan). Glyceol ® (Chugai Pharmaceutical Co., Ltd.) and hyaluronic acid was used for submucosal injection in ESD. An electrosurgical unit (VIO 300D; ERBE, Tubingen, Germany) was set according to the manufacturer's instructions and a mixed current was used for resection. As cold polypectomy was not adopted during the study period, all the procedures including polypectomy, EMR and ESD were performed using electrocautery (hot). PPB was treated endo scopically using soft coagulation, hemoclipping, or epinephrine injection. Student's ttest was used for continuous variables and chisquare test or Fisher's exact test was used for categorical variables. First, a univariate analysis was performed for all possible risk factors. The significant variables were taken as potential risk factors and were included in the multivariate logistic regression model. All P values were twosided and the results were considered significant when P values were < 0.05.
RESULTS
A total of 788 patients underwent polypectomy during the study period. Antithrombotic agents were prescribed to 210 (26.6%) patients; anticoagulants to 83 (10.5%), antiplatelets to 154 (19.5%), both to 28 (3.6%), dual antiplatelet agents to 59 (7.5%) and triple antiplatelet agents to 8 (1.0%) patients. Bridging therapy using intravenous UFH was adopted for 73 patients (9.3%) ( Table 1 ). All anticoagulants and antiplatelets were ceased before polypectomy except for aspirin or cilostazol in 19 cases. PPB occurred in 29 (3.7%) of 788 polypectomies performed. Four PPB patients required transfusion and none required surgery. None of the following were correlated with PPB: age, gender, polyp location, polyp size, polyp shape (flat vs sessile vs pedunculated), number of polyps resected, prophylactic clipping, resection method (polypectomy or EMR vs ESD), antiplatelets and antiplatelet plus heparin bridge therapy (Table  2) . Anticoagulants, heparin bridge therapy, and anticoagulants plus heparin bridge therapy (meaning that anticoagulants were substituted by heparin before polypectomy) were significantly associated with PPB ( Table 2) .
The multivariate logistic regression analysis revealed that anticoagulants and anticoagulants plus heparin bridge therapy were independent risk factors for PPB whereas heparin bridge therapy alone was not ( Table  3 ). The odds ratios of anticoagulants and anticoagulants A metaanalysis [15] and largescale studies [16, 17] also suggest that heparin bridge therapy might in crease bleeding after invasive procedures including polypectomy in patients taking anticoagulants. Notably, a randomized doubleblind placebocontrolled trial demonstrated that the incidence of major bleeding was higher in a bridging group than in a nobridging group whereas the incidence of arterial thromboembolism was similar in both groups (the BRIDGE trial) [17] . Our study also demonstrated that anticoagulants and anticoagulants plus heparinbridge therapy were independent risk factors for PPB. Anticoagulants were interrupted in all cases and PTINR at PPB was below the therapeutic range in most cases. Of 11 PPB cases using anticoagulants, 10 underwent heparin bridge therapy and 8 were on heparin at the time of PPB. Heparin bridge therapy might be responsible for PPB in patients taking anticoagulants, though APTT at PPB was elevated in only 2 cases. Heparin might have a synergic effect with anticoagulants, which is not measurable using APTT or PTINR.
Interestingly, antiplatelets plus heparin was not associated with PPB in our study. Previous studies demonstrated that aspirin is not a risk factor for PPB in conventional polypectomy [19, 20, 2325] . Yousfi et al [23] demonstrated that there was no statistically relevant difference in prior aspirin use before polypectomy in a bleeding group and matched controls. Manocha et al [25] demonstrated PPB rates of patients on aspirin
and NSAIDs vs those not on aspirin or NSAIDs (3.2% vs 3.0%). In contrast, polypectomy on clopidogrel is likely to have increased risk for PPB [8] . It might be prudent to postpone polypectomy for high thrombotic risk patients taking clopidogrel.
These results might reflect the mechanism of hemostatsis: anticoagulants work on the secondary hemostatsis process such as manufacturing of fibrin, while antiplatelet agents work on the primary hemostatsis such as the cohesion of platelets. As the secondary hemostasis is stronger than the primary, anticoagulants including heparin might cause PPB more frequently than antiplatelets [21] . plus heparin were 4.2 (95%CI: 1.12615.87, P = 0.033) and 9.8 (95%CI: 3.77125.443, P < 0.001), respectively.
Eleven PPB cases that took anticoagulants are summarized in Table 4 . Seven patients had atrial fibrillation, seven had valvular heart disease and one had cerebrovascular disease. Warfarin, dabigatran and antiplatelets were prescribed to 9, 2 and 3 patients, respectively. Anticoagulants and antiplatelets were ceased before polypectomy in all cases and heparin bridge therapy was carried out for 10 of 11 patients. Bleeding occurred 1 to 6 d after polypectomy. All PPB were successfully treated by endoscopy but re bleeding occurred in 3 cases. Seven patients resumed anticoagulants before PPB but the PTINR at PPB were within therapeutic range. Eight patients were still on heparin at PPB and APTT at PPB were elevated in 2 patients. A thromboembolic event occurred in a patient after ceasing anticoagulant treatment.
DISCUSSION
Our study demonstrated that anticoagulants and anticoagulants plus heparin bridge therapy might be independent risk factors for PPB despite periprocedural interruption. Several studies demonstrated a close correlation between PPB and anticoagulants [5, 13, 14, 1921] . Sawhney et al [5] demonstrated that resuming anticoa gulants following polypectomy was strongly associated with severe delayed PPB. Witt et al [13] also suggested the incidence of PPB was higher in patients receiving anticoagulation therapy, even though warfarin was interrupted for the procedure. It has been recently suggested that heparin bridge therapy might be associated with PPB after ceasing antithrombotic agents [15] . Inoue et al [14] demonstrated that the incidence of PPB was significantly higher in a heparin bridge group than in a nonheparin bridge group (20.0% vs 1.4%, respectively). Ishigami et al [22] also demonstrated that heparinbridging therapy is associated with a high risk of PPB regardless of polyp size. The present study had several limitations. First, this study was a retrospective study conducted at a single institution. The second limitation was the small sample size. As PPB is a rare complication with incidences ranging from 0.65% to 8.6% [46] , the small sample size of our study might have led to the ambiguous conclusion. Despite these limitations, we believe that the results of this study may have important implications for clinical practice. A further study on a larger scale will be needed.
In conclusion, patients taking anticoagulants have an increased risk of PPB, even if anticoagulants are interrupted before polypectomy. Heparinbridge therapy might be responsible for the increased PPB in patients taking anticoagulants. A prospective study to compare bridging with no bridging at polypectomy is warranted.
COMMENTS

Background
Post-polypectomy bleeding (PPB) is the most common adverse event of colonoscopic polypectomy. Past studies demonstrated risk factors for PPB but it is still controversial whether antithrombotic agents are associated with PPB. Major guidelines recommend ceasing anticoagulants before polypectomy and substituting by heparin (heparin-bridge) in high thrombotic risk cases.
Research frontiers
Recent studies suggest that heparin-bridge might increase bleeding after invasive procedure including polypectomy.
Innovations and breakthroughs
This study demonstrated that PPB increased in patients taking anticoagulants, despite they were ceased before polypectomy according to the guidelines. From the study results, the authors speculated that heparin-bridge might be responsible for PPB in patients taking anticoagulants.
Applications
When ceasing anticoagulants before polypectomy, no bridging might be better than heparin-bridge to reduce PPB. Prospective study is necessary to compare incidence of PPB as well as thrombotic events between 2 groups with and without heparin-bridge.
Terminology
In this study, PPB was defined as bleeding that occurred 6 h to 10 d after polypectomy and required endoscopic hemostasis.
